New drug SNP-610 aims to lower liver enzymes in NASH patients
NCT ID NCT03468556
First seen Mar 21, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study tests whether the drug SNP-610 can improve liver health in people with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. About 80 adults with high liver enzymes and at least 10% liver fat will receive either SNP-610 or a placebo for 3 months. The main goal is to see if the drug lowers liver enzyme levels, with additional checks on liver fat and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH - NONALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.